In re Vaxart, Inc. Securities Litigation
Case Number:
3:20-cv-05949
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Akin Gump
- Baker Botts
- Berman Tabacco
- Bleichmar Fonti
- Boies Schiller
- Conrad Metlitzky
- Goodwin Procter
- Hagens Berman
- Hanson Bridgett
- Paul Hastings
- Robbins LLP
- Scott&Scott
- Thompson Hine
- Willkie Farr
- Wilson Elser
Companies
Sectors & Industries:
-
April 30, 2024
Vaxart Investors Want Sanctions Over Deleted Texts
A group of Vaxart investors asked a California federal judge to issue sanctions against Armistice Capital LLC, which previously controlled Vaxart and allegedly sold $267 million worth of its Vaxart shares at inflated prices, saying the hedge fund and its executives purposely deleted text messages integral to the investors' claims.
-
August 22, 2022
Vaxart Investors Seek Initial OK Of $12M Deal In Fraud Suit
A proposed class of investors in Vaxart has urged a California federal court to give its initial OK to a $12 million settlement with the biotechnology company over allegations it pumped its stock price with deceptive headlines about a COVID-19 vaccine, arguing that it's a favorable outcome for investors.
-
December 22, 2021
Vaxart Can't Ditch Claims Co. Lied To Investors About Vaccine
A California federal judge kept alive a proposed securities class action Wednesday claiming the biotechnology company Vaxart pumped up its stock price with deceptive headlines about a COVID-19 vaccine, but tossed with leave to amend claims against a hedge fund that sold shares in the wake of Vaxart's statements.
-
September 30, 2021
Vaxart Buried Investors In 'Avalanche Of B.S.,' Judge Says
U.S. District Judge Vince Chhabria appeared skeptical Thursday of Vaxart's efforts to ditch a proposed securities class action claiming the biotechnology company artificially inflated its stock price with an allegedly deceptive headline about producing a COVID-19 vaccine candidate, saying the defendants "buried the investors in an avalanche of B.S."
-
May 13, 2021
Vaxart Investors Can Tweak Stock Claims Over COVID Vaccine
A group of investors suing Vaxart Inc. can amend their complaint to more clearly allege that the company artificially inflated its stock price through a press release with a deceptive headline about being a COVID-19 vaccine candidate, a California federal judge ruled on Thursday.
-
March 15, 2021
Biotech Co. Says It Never Lied About Its COVID Vaccine Work
Vaxart Inc. asked a California federal judge Friday to dismiss allegations that it misled investors about the prospects of its COVID-19 vaccine candidate, saying the securities suit is "premised on statements Vaxart never made."
-
December 09, 2020
Hagens Berman To Lead Investors' COVID-19 Vaccine Suit
A California federal judge on Wednesday appointed Hagens Berman Sobol Shapiro LLP lead counsel in a proposed class action filed by investors alleging San Francisco-based biotechnology company Vaxart Inc. lied about its COVID-19 vaccine candidate.
-
November 09, 2020
Biotech Co. Investors Battle To Lead COVID-19 Vaccine Suit
Investors vying for the lead role in a proposed class action alleging San Francisco-headquartered biotechnology company Vaxart Inc. lied about its COVID-19 vaccine candidate traded jabs in competing responses to each other's pleas to lead the proposed class.
-
August 24, 2020
Biotech Co. Lied About COVID-19 Vaccine, Investors Say
Investors in Vaxart Inc. accused the San Francisco-headquartered biotechnology company of lying about its COVID-19 vaccine candidate in order to inflate its stock price, according to a complaint filed Monday in California federal court.